A	O
PEBP2	B-protein
alpha/AML-1-related	I-protein
factor	I-protein
increases	O
osteocalcin	B-DNA
promoter	I-DNA
activity	O
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
.	O

To	O
identify	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
and	O
trans-acting	B-protein
factors	I-protein
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	B-DNA
of	O
a	O
mouse	B-DNA
osteocalcin	I-DNA
gene	I-DNA
,	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
.	O

In	O
this	O
promoter	O
,	O
we	O
identified	O
two	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
elements	I-DNA
(	O
Ducy	O
,	O
P.and	O
Karsenty	O
,	O
G.	O
(	O
1995	O
)	O
Mol.Cell.Biol.15	O
,	O
1858-1869	O
)	O
.	O

The	O
sequence	O
of	O
one	O
of	O
these	O
elements	B-DNA
,	O
OSE2	O
,	O
is	O
identical	O
to	O
the	O
DNA-binding	B-DNA
site	I-DNA
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mammalian	B-protein
homologues	I-protein
of	O
the	O
Drosophila	B-protein
Runt	I-protein
protein	I-protein
.	O

Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B-protein
protein	I-protein
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B-protein
proteins	I-protein
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	B-protein
,	O
binds	O
specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	B-protein
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	O
.	O

By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML-1B	B-protein
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	B-DNA
promoter	I-DNA
through	O
its	O
binding	O
to	O
OSE2	O
.	O

Lastly	O
,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
compared	O
with	O
T-cell	B-protein
nuclear	I-protein
extract-DNA	I-protein
complexes	I-protein
,	O
along	O
with	O
the	O
inability	O
of	O
OSF2	B-protein
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B-protein
alpha	I-protein
factors	I-protein
,	O
suggest	O
that	O
OSF2	B-protein
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B-protein
factors	I-protein
.	O

Thus	O
,	O
this	O
study	O
demonstrates	O
that	O
AML-1B	B-protein
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast-specific	B-DNA
gene	I-DNA
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B-DNA
cis-acting	I-DNA
element	I-DNA
and	O
presents	O
evidence	O
that	O
OSF2	B-protein
is	O
a	O
member	O
of	O
the	O
PEBP2	B-protein
alpha/AML-1	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

THs	NULL
JourNaL	NULL
or	NULL
BroLocicaL	NULL
CHEMISTRY	NULL
©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

270	NULL
,	NULL
No	NULL
.	NULL

52	NULL
,	NULL
Issue	NULL
of	NULL
December	NULL
29	NULL
,	NULL
pp	NULL
.	NULL

30973-30979	NULL
,	NULL
1995	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
A	NULL
PEBP2Z	NULL
«	NULL
/AML-1-related	NULL
Factor	NULL
Increases	NULL
Osteocalcin	NULL
Promoter	NULL
Activity	NULL
through	NULL
Its	NULL
Binding	NULL
to	NULL
an	NULL
Osteoblast-specific	NULL
cis-Acting	NULL
Element*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
September	NULL
7	NULL
,	NULL
1995	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
October	NULL
24	NULL
,	NULL
1995	NULL
)	NULL
Valérie	NULL
Geoffroy	NULL
$	NULL
§	NULL
,	NULL
Patricia	NULL
Ducy	NULL
?	NULL

and	NULL
Gérard	NULL
Karsenty	NULL
?	NULL

From	NULL
the	NULL
Department	NULL
of	NULL
Molecular	NULL
Genetics	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Houston	NULL
,	NULL
Texas	NULL
77030	NULL
To	NULL
identify	NULL
osteoblast-specific	NULL
cis-acting	NULL
elements	NULL
and	NULL
trans-acting	NULL
factors	NULL
,	NULL
we	NULL
initiated	NULL
an	NULL
analysis	NULL
of	NULL
the	NULL
promoter	NULL
of	NULL
a	NULL
mouse	NULL
osteocalcin	NULL
gene	NULL
,	NULL
an	NULL
osteoblast-specific	NULL
gene	NULL
.	NULL

In	NULL
this	NULL
promoter	NULL
,	NULL
we	NULL
identified	NULL
two	NULL
osteoblast-specific	NULL
cis-acting	NULL
elements	NULL
(	NULL
Ducy	NULL
,	NULL
P.	NULL
and	NULL
Karsenty	NULL
,	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
1858-1869	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
one	NULL
of	NULL
these	NULL
elements	NULL
,	NULL
OSE2	NULL
,	NULL
is	NULL
identical	NULL
to	NULL
the	NULL
DNA-binding	NULL
site	NULL
of	NULL
the	NULL
PEBP2	NULL
«	NULL
@	NULL
/AML-1	NULL
transcription	NULL
factors	NULL
,	NULL
the	NULL
mammalian	NULL
homologues	NULL
of	NULL
the	NULL
Drosophila	NULL
Runt	NULL
protein	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
,	NULL
using	NULL
nuclear	NULL
extracts	NULL
,	NULL
recombinant	NULL
protein	NULL
,	NULL
and	NULL
a	NULL
specific	NULL
antiserum	NULL
against	NULL
AML-1	NULL
proteins	NULL
in	NULL
DNA-binding	NULL
assays	NULL
,	NULL
that	NULL
one	NULL
member	NULL
of	NULL
this	NULL
family	NULL
,	NULL
AML-1B	NULL
,	NULL
binds	NULL
specifically	NULL
to	NULL
OSE2	NULL
and	NULL
is	NULL
immunologically	NULL
related	NULL
to	NULL
OSF2	NULL
,	NULL
the	NULL
factor	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
that	NULL
binds	NULL
to	NULL
OSE2	NULL
.	NULL

By	NULL
DNA	NULL
cotransfection	NULL
experiments	NULL
,	NULL
we	NULL
also	NULL
demonstrate	NULL
that	NULL
AML-1B	NULL
can	NULL
increase	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
short	NULL
osteocalcin	NULL
promoter	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
OSE2Z	NULL
.	NULL

Lastly	NULL
,	NULL
the	NULL
different	NULL
mobilities	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extract-	NULL
DNA	NULL
complexes	NULL
compared	NULL
with	NULL
T-cell	NULL
nuclear	NULL
extract-DNA	NULL
complexes	NULL
,	NULL
along	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
OSF2	NULL
to	NULL
be	NULL
up-regulated	NULL
by	NULL
retinoic	NULL
acid	NULL
,	NULL
unlike	NULL
the	NULL
other	NULL
PEBP2	NULL
«	NULL
factors	NULL
,	NULL
suggest	NULL
that	NULL
OSF2	NULL
is	NULL
a	NULL
new	NULL
member	NULL
of	NULL
this	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
study	NULL
demonstrates	NULL
that	NULL
AML-1B	NULL
can	NULL
increase	NULL
gene	NULL
expression	NULL
of	NULL
an	NULL
osteoblast-specific	NULL
gene	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
an	NULL
osteoblast-specific	NULL
cis-acting	NULL
element	NULL
and	NULL
presents	NULL
evidence	NULL
that	NULL
OSF2	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

To	NULL
date	NULL
no	NULL
osteoblast-specific	NULL
transcription	NULL
factor	NULL
has	NULL
been	NULL
identified	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
identify	NULL
such	NULL
factors	NULL
we	NULL
initiated	NULL
studies	NULL
of	NULL
the	NULL
cis-acting	NULL
elements	NULL
and	NULL
trans-acting	NULL
factors	NULL
that	NULL
control	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
osteocalcin	NULL
genes	NULL
in	NULL
osteoblasts	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Such	NULL
studies	NULL
are	NULL
crucial	NULL
for	NULL
a	NULL
better	NULL
comprehension	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
governing	NULL
osteoblast	NULL
differentiation	NULL
.	NULL

These	NULL
studies	NULL
should	NULL
also	NULL
increase	NULL
our	NULL
understanding	NULL
of	NULL
how	NULL
,	NULL
in	NULL
a	NULL
number	NULL
of	NULL
pathological	NULL
situations	NULL
,	NULL
the	NULL
synthesis	NULL
of	NULL
osteocalcin	NULL
is	NULL
altered	NULL
.	NULL

These	NULL
include	NULL
Paget	NULL
's	NULL
disease	NULL
,	NULL
secondary	NULL
hy-	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institute	NULL
Health	NULL
Grants	NULL
AR-41059	NULL
and	NULL
DE/AR-11290	NULL
and	NULL
Basic	NULL
Research	NULL
Award	NULL
IFY	NULL
92-0871	NULL
from	NULL
the	NULL
March	NULL
of	NULL
Dimes	NULL
Foundation	NULL
(	NULL
to	NULL
G.	NULL
K.	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

¢	NULL
The	NULL
first	NULL
two	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
and	NULL
should	NULL
be	NULL
both	NULL
considered	NULL
first	NULL
author	NULL
.	NULL

§	NULL
Supported	NULL
by	NULL
a	NULL
Fellowship	NULL
from	NULL
Institut	NULL
Scientifique	NULL
Roussel	NULL
.	NULL

«	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Dept	NULL
.	NULL

of	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Box	NULL
45	NULL
,	NULL
1515	NULL
Holcombe	NULL
Blvd	NULL
.	NULL

,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
713-792-8934	NULL
;	NULL
Fax	NULL
:	NULL
718-794-4394	NULL
;	NULL
E-mail	NULL
:	NULL
gkarsenty	NULL
@	NULL
molgen.mda.uth.tme.edu	NULL
.	NULL

perparathyroidism	NULL
,	NULL
and	NULL
some	NULL
forms	NULL
of	NULL
osteoporosis	NULL
(	NULL
for	NULL
review	NULL
see	NULL
Ref	NULL
.	NULL

2	NULL
)	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
in	NULL
these	NULL
situations	NULL
the	NULL
alterations	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
osteocalcin	NULL
genes	NULL
are	NULL
mediated	NULL
by	NULL
transcriptional	NULL
mechanisms	NULL
.	NULL

We	NULL
previously	NULL
identified	NULL
and	NULL
characterized	NULL
two	NULL
osteoblast-specific	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
mouse	NULL
osteocalcin	NULL
gene	NULL
2	NULL
(	NULL
mO0G2	NULL
)	NULL
(	NULL
1	NULL
)	NULL
.	NULL

In	NULL
DNA	NULL
transfection	NULL
experiments	NULL
,	NULL
these	NULL
two	NULL
elements	NULL
,	NULL
called	NULL
OSE1	NULL
and	NULL
OSE2	NULL
,	NULL
activate	NULL
transcription	NULL
in	NULL
osteoblastic	NULL
cell	NULL
lines	NULL
only	NULL
.	NULL

OSE1	NULL
,	NULL
the	NULL
most	NULL
proximal	NULL
element	NULL
,	NULL
binds	NULL
a	NULL
factor	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
mouse	NULL
primary	NULL
osteoblasts	NULL
before	NULL
they	NULL
are	NULL
able	NULL
to	NULL
mineralize	NULL
a	NULL
matrix	NULL
but	NULL
absent	NULL
from	NULL
nuclear	NULL
extracts	NULL
of	NULL
either	NULL
mineralizing	NULL
primary	NULL
osteoblasts	NULL
or	NULL
other	NULL
cell	NULL
lines	NULL
and	NULL
mouse	NULL
tissues	NULL
tested	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
the	NULL
factor	NULL
binding	NULL
to	NULL
OSE1	NULL
,	NULL
whose	NULL
characterization	NULL
is	NULL
underway	NULL
,	NULL
could	NULL
be	NULL
a	NULL
stage-specific	NULL
,	NULL
osteoblast-specific	NULL
transcription	NULL
factor	NULL
.	NULL

OSE2	NULL
,	NULL
the	NULL
second	NULL
osteoblast-specific	NULL
cis-acting	NULL
element	NULL
we	NULL
have	NULL
characterized	NULL
,	NULL
binds	NULL
a	NULL
factor	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
primary	NULL
osteoblasts	NULL
,	NULL
regardless	NULL
of	NULL
their	NULL
stage	NULL
of	NULL
differentiation	NULL
but	NULL
absent	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
any	NULL
other	NULL
cell	NULL
lines	NULL
or	NULL
mouse	NULL
tissues	NULL
tested	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
named	NULL
this	NULL
factor	NULL
osteoblast-specific	NULL
factor	NULL
2	NULL
or	NULL
OSF2	NULL
.	NULL

A	NULL
systematic	NULL
site-specific	NULL
mu-tagenesis	NULL
of	NULL
OSE2	NULL
enabled	NULL
us	NULL
to	NULL
define	NULL
a	NULL
core	NULL
sequence	NULL
of	NULL
8	NULL
bp	NULL
.	NULL
``	NULL

A	NULL
single	NULL
base	NULL
pair	NULL
substitution	NULL
mutation	NULL
of	NULL
any	NULL
of	NULL
these	NULL
8	NULL
bp	NULL
either	NULL
abolishes	NULL
or	NULL
greatly	NULL
reduces	NULL
the	NULL
binding	NULL
of	NULL
OSF2	NULL
to	NULL
OSE2	NULL
.	NULL

When	NULL
we	NULL
compared	NULL
the	NULL
OSE2	NULL
sequence	NULL
with	NULL
the	NULL
binding	NULL
sites	NULL
of	NULL
known	NULL
transcription	NULL
factors	NULL
(	NULL
3	NULL
)	NULL
,	NULL
we	NULL
found	NULL
an	NULL
identity	NULL
between	NULL
it	NULL
and	NULL
the	NULL
DNA-binding	NULL
site	NULL
of	NULL
AML-1	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
,	NULL
a	NULL
human	NULL
transcription	NULL
factor	NULL
,	NULL
and	NULL
of	NULL
PEBP2	NULL
«	NULL
,	NULL
the	NULL
mouse	NULL
conterpart	NULL
of	NULL
AML-1	NULL
(	NULL
6-9	NULL
)	NULL
.	NULL

AML-1	NULL
belongs	NULL
to	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
conserved	NULL
between	NULL
Drosophila	NULL
and	NULL
human	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
first	NULL
gene	NULL
to	NULL
be	NULL
identified	NULL
in	NULL
this	NULL
family	NULL
was	NULL
the	NULL
Drosophila	NULL
segmentation	NULL
gene	NULL
runt	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
mouse	NULL
homologues	NULL
of	NULL
runt	NULL
include	NULL
PEBP2	NULL
@	NULL
A	NULL
(	NULL
6	NULL
)	NULL
and	NULL
PEBP2	NULL
«	NULL
B	NULL
(	NULL
7	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
three	NULL
human	NULL
genes	NULL
,	NULL
AML-1A	NULL
(	NULL
4	NULL
)	NULL
,	NULL
AML-1B	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
PEBP2	NULL
@	NULL
C	NULL
(	NULL
9	NULL
)	NULL
,	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

The	NULL
mouse	NULL
and	NULL
human	NULL
genes	NULL
have	NULL
in	NULL
common	NULL
with	NULL
their	NULL
Drosophila	NULL
counterpart	NULL
a	NULL
conserved	NULL
domain	NULL
called	NULL
the	NULL
runt	NULL
domain	NULL
,	NULL
which	NULL
encodes	NULL
a	NULL
128-amino	NULL
acids	NULL
peptide	NULL
.	NULL

This	NULL
domain	NULL
is	NULL
responsible	NULL
for	NULL
DNA	NULL
binding	NULL
and	NULL
heterodimerization	NULL
(	NULL
7	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
PEBP2	NULL
@	NULL
/AML-1	NULL
factors	NULL
identified	NULL
and	NULL
studied	NULL
have	NULL
all	NULL
been	NULL
implicated	NULL
in	NULL
myeloid	NULL
cell-specific	NULL
gene	NULL
expression	NULL
(	NULL
5	NULL
,	NULL
7	NULL
,	NULL
12-14	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
conducted	NULL
a	NULL
biochemical	NULL
,	NULL
immunological	NULL
,	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
OSF2	NULL
,	NULL
the	NULL
factor	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
and	NULL
binding	NULL
to	NULL
OSEZ	NULL
.	NULL

We	NULL
present	NULL
evidence	NULL
that	NULL
OSF2	NULL
is	NULL
immunologically	NULL
related	NULL
to	NULL
the	NULL
PEBP2	NULL
@	NULL
/	NULL
AML-1	NULL
transcription	NULL
factors	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
by	NULL
DNA	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
CMV	NULL
,	NULL
cytomegalovirus	NULL
;	NULL
DHFR	NULL
,	NULL
dihydrofolate	NULL
reductase	NULL
;	NULL
RA	NULL
,	NULL
retinoic	NULL
acid	NULL
;	NULL
ivt	NULL
,	NULL
in	NULL
vitro	NULL
transcribed	NULL
and	NULL
translated	NULL
;	NULL
GRA	NULL
,	NULL
gel	NULL
retardation	NULL
assays	NULL
;	NULL
lue	NULL
,	NULL
luciferase	NULL
.	NULL

309783	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
30974	NULL
Osteoblast-specific	NULL
Gene	NULL
Expression	NULL
,	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
Factors	NULL
TaBtE	NULL
I	NULL
Oligonucleotides	NULL
used	NULL
in	NULL
this	NULL
study	NULL
The	NULL
mutation	NULL
substitutions	NULL
introduced	NULL
in	NULL
the	NULL
OSE2	NULL
and	NULL
PEBP2	NULL
@	NULL
binding	NULL
sites	NULL
are	NULL
represented	NULL
in	NULL
bold	NULL
.	NULL

Name	NULL
Sequence	NULL
Reference	NULL
OSE2	NULL
wild-type	NULL
GATCCGCTGCAATCACCAACCACAGCA	NULL
1	NULL
GCGACGTTAGTGGTTGGTGTCGTCTAG	NULL
OSE2	NULL
mutant	NULL
GATCCGCTGCAATCACCAAGAACAGCA	NULL
1	NULL
GCGACGTTAGTGGTTCTTGTCGTCTAG	NULL
PEBP2a	NULL
wild-type	NULL
GGGGATATCTGTGGTAAGCA	NULL
20	NULL
CCTATAGACACCATTCGTGG	NULL
PEBP2a	NULL
mutant	NULL
GGGGATATCTGTTCTAAGCA	NULL
This	NULL
study	NULL
CCTATAGACAAGATTCGTGG	NULL
Spl	NULL
AGGGCGGGGATTGAGGCGGG	NULL
21	NULL
CCCGCCCCTAACTCCGCCCA	NULL
cotransfection	NULL
experiments	NULL
that	NULL
one	NULL
member	NULL
of	NULL
this	NULL
family	NULL
,	NULL
Reference	NULL
AML-1B	NULL
,	NULL
can	NULL
activate	NULL
transcription	NULL
of	NULL
a	NULL
short	NULL
osteocalcin	NULL
pro-	NULL
5	NULL
:	NULL
TACCACA	NULL
3	NULL
20	NULL
moter	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
OSE2	NULL
.	NULL

Taken	NULL
together	NULL
these	NULL
re-	NULL
5	NULL
!	NULL

GACCGCA	NULL
#	NULL
22	NULL
sults	NULL
indicate	NULL
that	NULL
either	NULL
an	NULL
already	NULL
described	NULL
or	NULL
a	NULL
new	NULL
mem-	NULL
PEBP20	NULL
!	NULL

binding	NULL
sites	NULL
:	NULL
5	NULL
!	NULL

AGCCACA	NULL
3	NULL
13	NULL
ber	NULL
of	NULL
the	NULL
PEBP2	NULL
@	NULL
/AML-1B	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
is	NULL
5	NULL
!	NULL

GGCCACA	NULL
3	NULL
12	NULL
involved	NULL
in	NULL
osteoblast-specific	NULL
gene	NULL
expression	NULL
.	NULL

5	NULL
!	NULL

AACCACA	NULL
3	NULL
12	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
AML-1	NULL
binding	NULL
site	NULL
:	NULL
5	NULL
!	NULL

-ACCaCA	NULL
3	NULL
4	NULL
Cell	NULL
Culture	NULL
and	NULL
DNA	NULL
Transfection-Mouse	NULL
F9	NULL
teratocarcinoma	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Eagle	NULL
's	NULL
minimal	NULL
essential	NULL
medium/10	NULL
%	NULL
fetal	NULL
bovine	NULL
AML-1/PEBP2	NULL
«	NULL
serum	NULL
.	NULL

The	NULL
ROS	NULL
17/2.8	NULL
osteosarcoma	NULL
cell	NULL
line	NULL
and	NULL
the	NULL
mouse	NULL
primary	NULL
consensus	NULL
binding	NULL
site	NULL
:	NULL
5	NULL
!	NULL

~ruCCmaCA	NULL
3	NULL
:	NULL
osteoblasts	NULL
were	NULL
cultured	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
human	NULL
T-lymphoblastic	NULL
cell	NULL
lines	NULL
Molt	NULL
4	NULL
and	NULL
Jurkat	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
OSE2	NULL
sequence	NULL
:	NULL
5	NULL
AACCACA	NULL
3	NULL
1	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
day	NULL
before	NULL
transfection	NULL
,	NULL
F9	NULL
cells	NULL
were	NULL
plated	NULL
on	NULL
10-cm	NULL
dishes	NULL
at	NULL
a	NULL
density	NULL
of	NULL
5	NULL
X	NULL
10°	NULL
cells/dish	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipi-tation	NULL
method	NULL
(	NULL
15	NULL
)	NULL
,	NULL
using	NULL
5	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
expression	NULL
vector	NULL
,	NULL
and	NULL
2	NULL
pg	NULL
of	NULL
pRSV/8Gal	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
sodium	NULL
phosphate	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
)	NULL
and	NULL
then	NULL
incubated	NULL
in	NULL
regular	NULL
medium	NULL
for	NULL
24	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
by	NULL
scraping	NULL
them	NULL
into	NULL
0.3	NULL
ml	NULL
of	NULL
0.25	NULL
M	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
and	NULL
lysed	NULL
by	NULL
three	NULL
cycles	NULL
of	NULL
freezing-thawing	NULL
.	NULL

-Galactosidase	NULL
activities	NULL
present	NULL
in	NULL
each	NULL
lysate	NULL
,	NULL
measured	NULL
by	NULL
a	NULL
colorimetric	NULL
enzyme	NULL
assay	NULL
using	NULL
resorufin	NULL
B-D-galactopyranoside	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
as	NULL
a	NULL
substrate	NULL
,	NULL
were	NULL
used	NULL
to	NULL
normalize	NULL
the	NULL
transfection	NULL
efficiency	NULL
between	NULL
experiments	NULL
.	NULL

Luciferase	NULL
activities	NULL
were	NULL
assayed	NULL
by	NULL
using	NULL
a	NULL
Monolight	NULL
2010	NULL
luminometer	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
)	NULL
and	NULL
D-lucife-rin	NULL
substrate	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
)	NULL
in	NULL
100	NULL
mM	NULL
Tris-HC	NULL
]	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
ATP	NULL
,	NULL
15	NULL
mm	NULL
MgSQO	NULL
,	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
.	NULL

To	NULL
induce	NULL
their	NULL
differentiation	NULL
,	NULL
the	NULL
F9	NULL
cells	NULL
were	NULL
plated	NULL
and	NULL
treated	NULL
with	NULL
1	NULL
uM	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
for	NULL
5	NULL
days	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

On	NULL
the	NULL
second	NULL
day	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
changed	NULL
,	NULL
and	NULL
RA	NULL
was	NULL
added	NULL
again	NULL
.	NULL

More	NULL
than	NULL
95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
became	NULL
differentiated	NULL
as	NULL
judged	NULL
microscopically	NULL
on	NULL
the	NULL
fifth	NULL
day	NULL
of	NULL
incubation	NULL
.	NULL

ROS	NULL
17/2.8	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
RA	NULL
in	NULL
the	NULL
same	NULL
conditions	NULL
and	NULL
for	NULL
the	NULL
same	NULL
time	NULL
.	NULL

In	NULL
Vitro	NULL
Transcription	NULL
and	NULL
Translation-The	NULL
AML-1B	NULL
plasmid	NULL
DNA	NULL
was	NULL
transcribed/translated	NULL
using	NULL
the	NULL
TnT	NULL
kit	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
unlabeled	NULL
or	NULL
*°S-labeled	NULL
methionine	NULL
for	NULL
90	NULL
min	NULL
at	NULL
30	NULL
°C	NULL
in	NULL
parallel	NULL
.	NULL

°°8-labeled	NULL
proteins	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
and	NULL
unlabeled	NULL
products	NULL
were	NULL
used	NULL
in	NULL
a	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

The	NULL
ivt	NULL
AML-1B	NULL
plasmid	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
S.	NULL
Hiebert	NULL
(	NULL
St.	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hospital	NULL
,	NULL
Memphis	NULL
,	NULL
TN	NULL
)	NULL
.	NULL

DNA	NULL
Constructions-Details	NULL
of	NULL
the	NULL
construction	NULL
of	NULL
the	NULL
reporter	NULL
plasmids	NULL
p34-lue	NULL
,	NULL
and	NULL
p6OSE2-lue	NULL
,	NULL
p6OSE2	NULL
m-luce	NULL
,	NULL
and	NULL
pGOSE1-lue	NULL
,	NULL
vectors	NULL
containing	NULL
,	NULL
respectively	NULL
,	NULL
6	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
,	NULL
6	NULL
copies	NULL
of	NULL
the	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
,	NULL
or	NULL
6	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
OSE1	NULL
oligonucleotide	NULL
in	NULL
front	NULL
of	NULL
the	NULL
-34/+13	NULL
mOG2	NULL
promoter-luciferase	NULL
(	NULL
luc	NULL
)	NULL
chimeric	NULL
gene	NULL
,	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
construction	NULL
of	NULL
expression	NULL
vectors	NULL
containing	NULL
the	NULL
AML-1B	NULL
eDNA	NULL
cloned	NULL
,	NULL
in	NULL
the	NULL
correct	NULL
or	NULL
opposite	NULL
orientation	NULL
,	NULL
downstream	NULL
of	NULL
the	NULL
CMV5	NULL
promoter	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
5	NULL
)	NULL
.	NULL

These	NULL
expression	NULL
vectors	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr	NULL
S.	NULL
Hiebert	NULL
.	NULL

The	NULL
construction	NULL
of	NULL
the	NULL
expression	NULL
vector	NULL
containing	NULL
the	NULL
c-Myb	NULL
cDNA	NULL
cloned	NULL
downstream	NULL
of	NULL
the	NULL
DHFR	NULL
promoter	NULL
has	NULL
been	NULL
reported	NULL
earlier	NULL
(	NULL
17	NULL
)	NULL
,	NULL
this	NULL
plasmid	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
B.	NULL
Calabreta	NULL
(	NULL
Jefferson	NULL
Cancer	NULL
Institute	NULL
,	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Nuclear	NULL
Extract	NULL
Preparation	NULL
and	NULL
DNA	NULL
Binding	NULL
Assays-Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
and	NULL
Schreiber	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
.	NULL

Buffers	NULL
for	NULL
the	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
contained	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
and	NULL
the	NULL
protease	NULL
inhibitors	NULL
0.5	NULL
mM	NULL
phenylmethylsul-	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Comparison	NULL
of	NULL
PEBP2	NULL
«	NULL
and	NULL
AML-1	NULL
binding	NULL
sequences	NULL
and	NULL
OSE2	NULL
sequence	NULL
.	NULL

The	NULL
identical	NULL
bp	NULL
between	NULL
OSE2	NULL
and	NULL
the	NULL
consensus	NULL
PEBP2	NULL
«	NULL
@	NULL
/AML-1	NULL
binding	NULL
site	NULL
are	NULL
indicated	NULL
in	NULL
bold	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
PEBP2	NULL
@	NULL
binding	NULL
site	NULL
used	NULL
in	NULL
this	NULL
study	NULL
is	NULL
underlined	NULL
.	NULL

fonyl	NULL
fluoride	NULL
and	NULL
10	NULL
ug/ml	NULL
of	NULL
leupeptin	NULL
and	NULL
pepstatin	NULL
.	NULL

For	NULL
the	NULL
gel	NULL
retardation	NULL
assays	NULL
(	NULL
GRA	NULL
)	NULL
,	NULL
labeled	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
1	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
and	NULL
electro-phoresis	NULL
conditions	NULL
were	NULL
also	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
1	NULL
,	NULL
5	NULL
)	NULL
.	NULL

The	NULL
oligonucleotides	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
presented	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

For	NULL
competition	NULL
experiments	NULL
,	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
double-stranded	NULL
unlabeled	NULL
oligonucleotide	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
with	NULL
the	NULL
other	NULL
compo-nents	NULL
.	NULL

For	NULL
experiments	NULL
using	NULL
anti-AML-1B	NULL
antiserum	NULL
,	NULL
which	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
17-amino	NULL
acid	NULL
N-terminal	NULL
peptide	NULL
of	NULL
AML-1	NULL
(	NULL
4	NULL
)	NULL
,	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
anti-AML-1B	NULL
antiserum	NULL
was	NULL
added	NULL
either	NULL
with	NULL
or	NULL
without	NULL
the	NULL
antigenic	NULL
peptide	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
30	NULL
min	NULL
before	NULL
the	NULL
probe	NULL
.	NULL

Anti-AML-1B	NULL
antiserum	NULL
and	NULL
AML-1B	NULL
antigenic	NULL
peptide	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr	NULL
S.	NULL
Hiebert	NULL
.	NULL

When	NULL
needed	NULL
,	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
a	NULL
purified	NULL
antibody	NULL
raised	NULL
against	NULL
the	NULL
transcription	NULL
factor	NULL
c-Myb	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
Incorporated	NULL
)	NULL
was	NULL
added	NULL
during	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

RESULTS	NULL
The	NULL
OSE2	NULL
Sequence	NULL
and	NULL
PEBP2	NULL
«	NULL
/	NULL
AML-1	NULL
Binding	NULL
Sites	NULL
Are	NULL
Similar-A	NULL
comparison	NULL
of	NULL
the	NULL
OSE2	NULL
sequence	NULL
5	NULL
'	NULL
AACCACA	NULL
3	NULL
``	NULL
with	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
known	NULL
transcription	NULL
factors	NULL
(	NULL
3	NULL
)	NULL
showed	NULL
that	NULL
the	NULL
most	NULL
homologous	NULL
binding	NULL
sites	NULL
were	NULL
those	NULL
for	NULL
AML-1	NULL
and	NULL
PEBP2	NULL
«	NULL
@	NULL
,	NULL
a	NULL
group	NULL
of	NULL
transcription	NULL
factors	NULL
conserved	NULL
between	NULL
mouse	NULL
and	NULL
human	NULL
that	NULL
recognize	NULL
the	NULL
DNA	NULL
sequence	NULL
5'PuCCPuCA3	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Given	NULL
this	NULL
sequence	NULL
homology	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
oligonucleotides	NULL
containing	NULL
either	NULL
the	NULL
OSE2	NULL
sequence	NULL
or	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
PEBP2	NULL
«	NULL
binding	NULL
site	NULL
(	NULL
20	NULL
)	NULL
would	NULL
bind	NULL
similar	NULL
factors	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
ROS	NULL
17/2.8	NULL
cells	NULL
.	NULL

When	NULL
we	NULL
used	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
GRA	NULL
and	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
as	NULL
a	NULL
source	NULL
of	NULL
proteins	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
protein-DNA	NULL
complex	NULL
already	NULL
described	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
50-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
or	NULL
the	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
2-7	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
unaffected	NULL
by	NULL
100-fold	NULL
of	NULL
a	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
2-bp	NULL
substitution	NULL
mutation	NULL
or	NULL
of	NULL
a	NULL
mutant	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
same	NULL
2-bp	NULL
substitution	NULL
mutation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
.	NULL

When	NULL
we	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Osteoblast-specific	NULL
Gene	NULL
Expression	NULL
,	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
Factors	NULL
30975	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

OSF2	NULL
binds	NULL
to	NULL
the	NULL
OSE2	NULL
oli-	NULL
&	NULL
-	NULL
§	NULL
ao	NULL
g	NULL
gonucleotide	NULL
and	NULL
the	NULL
PEBP2	NULL
«	NULL
oligo-	NULL
a	NULL
£	NULL
Ao	NULL
5	NULL
nucleotide	NULL
.	NULL

DNA	NULL
binding	NULL
was	NULL
analyzed	NULL
0	NULL
&	NULL
0	NULL
°	NULL
&	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

Lanes	NULL
1-9	NULL
,	NULL
la-	NULL
wtOSE2	NULL
-	NULL
wtPEBP	NULL
.	NULL

a	NULL
-	NULL
E0	NULL
2	NULL
wiOSE2	NULL
-	NULL
wiPEBP2	NULL
«	NULL
-	NULL
E0	NULL
E	NULL
beled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
was	NULL
tto	NULL
-	NULL
3	NULL
&	NULL
I	NULL
rt	NULL
zo	NULL
g	NULL
incubated	NULL
with	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
ex-	NULL
Competitor	NULL
:	NULL
-	NULL
&	NULL
€	NULL
é	NULL
&	NULL
&	NULL
g	NULL
B	NULL
é	NULL
Competitor	NULL
:	NULL
-	NULL
#	NULL
$	NULL
§	NULL
g	NULL
$	NULL
§	NULL
&	NULL
§	NULL
tracts	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
either	NULL
the	NULL
same	NULL
unlabeled	NULL
wild-type	NULL
(	NULL
w¢	NULL
)	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
,	NULL
the	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
@	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
,	NULL
the	NULL
mutant	NULL
(	NULL
mut	NULL
)	NULL
OSE2	NULL
#	NULL
4	NULL
oligonucleotide	NULL
(	NULL
Zane	NULL
8	NULL
)	NULL
,	NULL
or	NULL
the	NULL
mutant	NULL
PEBP2	NULL
@	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Lanes	NULL
10-18	NULL
,	NULL
labeled	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
either	NULL
the	NULL
unlabeled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
anes	NULL
11-13	NULL
)	NULL
,	NULL
the	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
@	NULL
oligonucleotide	NULL
(	NULL
lanes	NULL
14-16	NULL
)	NULL
,	NULL
the	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Zane	NULL
17	NULL
)	NULL
,	NULL
or	NULL
the	NULL
mutant	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
(	NULL
Jane	NULL
18	NULL
)	NULL
.	NULL

Molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitors	NULL
are	NULL
indicated	NULL
.	NULL

A	NULL
minus	NULL
sign	NULL
indicates	NULL
no	NULL
competitor	NULL
.	NULL

Io	NULL
2	NULL
%	NULL
O30	NULL
4	NULL
oS	NULL
GRA	NULL
the	NULL
PEBP2	NULL
@	NULL
oligonucleotide	NULL
and	NULL
incubated	NULL
it	NULL
with	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
,	NULL
we	NULL
detected	NULL
a	NULL
protein-DNA	NULL
complex	NULL
that	NULL
had	NULL
the	NULL
same	NULL
mobility	NULL
pattern	NULL
as	NULL
the	NULL
one	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
these	NULL
nuclear	NULL
extracts	NULL
with	NULL
the	NULL
labeled	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Formation	NULL
of	NULL
this	NULL
protein-DNA	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
50-100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
or	NULL
the	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lames	NULL
11-16	NULL
)	NULL
.	NULL

A	NULL
large	NULL
excess	NULL
of	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
or	NULL
mutant	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
2-bp	NULL
substitution	NULL
mutation	NULL
failed	NULL
to	NULL
inhibit	NULL
this	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
equal	NULL
mobility	NULL
of	NULL
the	NULL
complexes	NULL
and	NULL
the	NULL
results	NULL
of	NULL
the	NULL
DNA	NULL
competition	NULL
experiments	NULL
indicate	NULL
that	NULL
OSF2	NULL
,	NULL
the	NULL
factor	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
and	NULL
binding	NULL
to	NULL
OSE2	NULL
,	NULL
is	NULL
related	NULL
to	NULL
the	NULL
PEBP2	NULL
«	NULL
@	NULL
/AML-1	NULL
proteins	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
in	NULL
DNA	NULL
competition	NULL
experiments	NULL
the	NULL
same	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
and	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
was	NULL
necessary	NULL
to	NULL
abolish	NULL
binding	NULL
of	NULL
OSF2	NULL
to	NULL
either	NULL
probe	NULL
suggests	NULL
that	NULL
OSF2	NULL
has	NULL
a	NULL
similar	NULL
affinity	NULL
for	NULL
the	NULL
PEBP2	NULL
«	NULL
binding	NULL
site	NULL
and	NULL
OSE2	NULL
.	NULL

Recombinant	NULL
AML-1B	NULL
Protein	NULL
Binds	NULL
Specifically	NULL
to	NULL
OSE2-We	NULL
then	NULL
used	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
to	NULL
perform	NULL
GRA	NULL
.	NULL

This	NULL
ivt	NULL
protein	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
PEBP2a	NULL
«	NULL
binding	NULL
site	NULL
and	NULL
to	NULL
the	NULL
AML-1B	NULL
binding	NULL
site	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
bound	NULL
to	NULL
the	NULL
labeled	NULL
OSE2	NULL
oligonucleotide	NULL
;	NULL
this	NULL
binding	NULL
was	NULL
specific	NULL
because	NULL
it	NULL
could	NULL
be	NULL
abolished	NULL
by	NULL
a	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
but	NULL
not	NULL
by	NULL
a	NULL
400-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
1-4	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
we	NULL
performed	NULL
the	NULL
same	NULL
experiment	NULL
using	NULL
the	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
and	NULL
showed	NULL
that	NULL
ivt	NULL
AML-1B	NULL
bound	NULL
specifically	NULL
to	NULL
this	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lanes	NULL
5-11	NULL
)	NULL
.	NULL

The	NULL
ivt	NULL
AML-1B-DNA	NULL
complex	NULL
always	NULL
had	NULL
a	NULL
slightly	NULL
slower	NULL
mobility	NULL
when	NULL
we	NULL
used	NULL
the	NULL
PEBP2	NULL
«	NULL
@	NULL
oligonucleotide	NULL
than	NULL
when	NULL
we	NULL
used	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
.	NULL

We	NULL
then	NULL
used	NULL
an	NULL
antiserum	NULL
directed	NULL
against	NULL
the	NULL
N-terminal	NULL
part	NULL
of	NULL
AML-1B	NULL
in	NULL
GRA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
this	NULL
antibody	NULL
inhibited	NULL
binding	NULL
of	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
.	NULL

To	NULL
show	NULL
the	NULL
specificity	NULL
of	NULL
this	NULL
interaction	NULL
,	NULL
we	NULL
performed	NULL
two	NULL
control	NULL
experiments	NULL
.	NULL

First	NULL
,	NULL
when	NULL
added	NULL
during	NULL
the	NULL
binding	NULL
reaction	NULL
,	NULL
the	NULL
peptide	NULL
against	NULL
which	NULL
this	NULL
antiserum	NULL
was	NULL
raised	NULL
prevented	NULL
the	NULL
abolition	NULL
of	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
a	NULL
purified	NULL
antibody	NULL
against	NULL
an	NULL
unrelated	NULL
transcription	NULL
factor	NULL
,	NULL
c-Myb	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
to	NULL
the	NULL
labeled	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
ivt	NULL
AML-1B	NULL
to	NULL
the	NULL
PEBP2a	NULL
«	NULL
oligonucleotide	NULL
was	NULL
abolished	NULL
specifically	NULL
by	NULL
the	NULL
anti-AML-1B	NULL
‘	NULL
Rw	NULL
#	NULL
#	NULL
+s	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
.	NULL

18	NULL
antiserum	NULL
but	NULL
not	NULL
by	NULL
the	NULL
unrelated	NULL
anti-c-Myb	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lanes	NULL
6-10	NULL
)	NULL
.	NULL

We	NULL
then	NULL
asked	NULL
whether	NULL
the	NULL
anti-AML-1B	NULL
antiserum	NULL
could	NULL
alter	NULL
the	NULL
binding	NULL
of	NULL
ROS	NULL
17/2.8	NULL
or	NULL
mouse	NULL
primary	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
to	NULL
the	NULL
labeled	NULL
OSE2	NULL
oligonucleotide	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
increasing	NULL
amounts	NULL
of	NULL
anti-AML-1B	NULL
antiserum	NULL
substantially	NULL
decreased	NULL
or	NULL
abolished	NULL
the	NULL
binding	NULL
of	NULL
either	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
or	NULL
mouse	NULL
primary	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
2-5	NULL
and	NULL
11-14	NULL
)	NULL
.	NULL

As	NULL
was	NULL
the	NULL
case	NULL
for	NULL
the	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
,	NULL
this	NULL
decreased	NULL
binding	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
during	NULL
the	NULL
binding	NULL
reaction	NULL
of	NULL
the	NULL
AML-1	NULL
antigenic	NULL
peptide	NULL
against	NULL
which	NULL
the	NULL
antiserum	NULL
was	NULL
raised	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
17	NULL
)	NULL
.	NULL

This	NULL
inhibition	NULL
of	NULL
binding	NULL
was	NULL
not	NULL
observed	NULL
when	NULL
we	NULL
used	NULL
a	NULL
10-fold	NULL
higher	NULL
amount	NULL
of	NULL
an	NULL
anti-c-Myb	NULL
antibody	NULL
as	NULL
a	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
18	NULL
)	NULL
.	NULL

We	NULL
chose	NULL
an	NULL
antibody	NULL
against	NULL
c-Myb	NULL
because	NULL
c-Myb	NULL
is	NULL
also	NULL
a	NULL
myeloid-specific	NULL
transcription	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
sequence	NULL
related	NULL
but	NULL
not	NULL
identical	NULL
to	NULL
the	NULL
OSE2	NULL
sequence	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
the	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
abolition	NULL
of	NULL
binding	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
anti-AML-1B	NULL
antiserum	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
,	NULL
indicates	NULL
that	NULL
a	NULL
PEBP2	NULL
«	NULL
@	NULL
/AML-1-related	NULL
protein	NULL
is	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
and	NULL
binds	NULL
specifically	NULL
to	NULL
OSE2	NULL
.	NULL

As	NULL
stated	NULL
above	NULL
we	NULL
named	NULL
this	NULL
PEBP2	NULL
«	NULL
@	NULL
/AML-l-related	NULL
factor	NULL
OSF2	NULL
.	NULL

We	NULL
next	NULL
asked	NULL
whether	NULL
we	NULL
could	NULL
distinguish	NULL
OSF2	NULL
from	NULL
the	NULL
other	NULL
PEBP2	NULL
«	NULL
factors	NULL
.	NULL

OSF2	NULL
,	NULL
the	NULL
OSE2	NULL
Binding	NULL
Factor	NULL
,	NULL
and	NULL
the	NULL
Factor	NULL
Present	NULL
in	NULL
Lymphocytes	NULL
Nuclear	NULL
Extracts	NULL
Have	NULL
Different	NULL
Mobilities	NULL
in	NULL
GRA-We	NULL
showed	NULL
earlier	NULL
that	NULL
OSF2	NULL
was	NULL
present	NULL
only	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
primary	NULL
osteoblasts	NULL
or	NULL
osteoblastic	NULL
cell	NULL
lines	NULL
(	NULL
1	NULL
)	NULL
.	NULL

This	NULL
initial	NULL
analysis	NULL
included	NULL
nuclear	NULL
extracts	NULL
of	NULL
a	NULL
mouse	NULL
B-cell	NULL
line	NULL
as	NULL
one	NULL
of	NULL
our	NULL
negative	NULL
controls	NULL
but	NULL
did	NULL
not	NULL
include	NULL
nuclear	NULL
extracts	NULL
of	NULL
T-cell	NULL
lines	NULL
or	NULL
other	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
known	NULL
to	NULL
contain	NULL
PEBP2	NULL
«	NULL
factors	NULL
.	NULL

Given	NULL
the	NULL
results	NULL
presented	NULL
above	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
GRA	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
mouse	NULL
primary	NULL
osteoblasts	NULL
,	NULL
ROS	NULL
17/2.8	NULL
osteoblastic	NULL
cells	NULL
,	NULL
the	NULL
S	NULL
194	NULL
mouse	NULL
B-cells	NULL
,	NULL
and	NULL
two	NULL
different	NULL
human	NULL
T-cell	NULL
lines	NULL
known	NULL
to	NULL
contain	NULL
PEBP2	NULL
«	NULL
factors	NULL
,	NULL
the	NULL
Jurkat	NULL
and	NULL
the	NULL
Molt	NULL
4	NULL
cell	NULL
lines	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
with	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
or	NULL
the	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
were	NULL
different	NULL
from	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
human	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
with	NULL
the	NULL
same	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
1-2	NULL
,	NULL
4-5	NULL
,	NULL
6-7	NULL
,	NULL
and	NULL
9-10	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
protein-DNA	NULL
complex	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
mouse	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
30976	NULL
y	NULL
A	NULL
*	NULL
g	NULL
f	NULL
R	NULL
A	NULL
0	NULL
&	NULL
§0	NULL
&	NULL
0	NULL
&	NULL
&	NULL
w	NULL
$	NULL
un	NULL
©	NULL
E	NULL
A.	NULL
O	NULL
t	NULL
O	NULL
to	NULL
Ca	NULL
to	NULL
x	NULL
5	NULL
l	NULL
J	NULL
3	NULL
Eo	NULL
E	NULL
Eo	NULL
£	NULL
Eo	NULL
f	NULL
&	NULL
,	NULL
woop	NULL
x	NULL
®o	NULL
®	NULL
x	NULL
Competitor	NULL
:	NULL
-	NULL
S	NULL
$	NULL
§	NULL
-	NULL
=	NULL
é	NULL
§	NULL
S	NULL
&	NULL
g	NULL
&	NULL
5	NULL
a	NULL
%	NULL
%	NULL
a	NULL
4	NULL
UE	NULL
s	NULL
C-	NULL
%	NULL
|	NULL
1°	NULL
20	NULL
3	NULL
4	NULL
§	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
B	NULL
wt	NULL
OSE2	NULL
wi	NULL
PEBP2c	NULL
ivt	NULL
AML-IB	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+o	NULL
+	NULL
4	NULL
0+	NULL
+	NULL
+	NULL
pre-immune	NULL
serum	NULL
x	NULL
anti-AML-1B	NULL
antiserum	NULL
+	NULL
+	NULL
+	NULL
AML-1B	NULL
antigenic	NULL
peptide	NULL
+	NULL
+	NULL
anti-c-myb	NULL
antibody	NULL
+	NULL
+	NULL
y	NULL
b	NULL
.	NULL

0	NULL
o	NULL
1	NULL
2	NULL
3	NULL
4	NULL
500	NULL
6	NULL
708	NULL
9	NULL
10	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Binding	NULL
of	NULL
recombinant	NULL
AML-1B	NULL
protein	NULL
to	NULL
the	NULL
OSE2	NULL
or	NULL
PEBP2	NULL
a	NULL
oligonucleotides	NULL
.	NULL

DNA	NULL
binding	NULL
was	NULL
analyzed	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

A	NULL
,	NULL
a	NULL
labeled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Zanes	NULL
1-4	NULL
)	NULL
or	NULL
a	NULL
labeled	NULL
wild-type	NULL
PEBP2a	NULL
oligonucleotide	NULL
(	NULL
Zanes	NULL
5-17	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
in	NULL
vitro	NULL
transcribed	NULL
and	NULL
translated	NULL
AML-1B	NULL
protein	NULL
(	NULL
ivt	NULL
AML-1B	NULL
)	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
200-	NULL
and	NULL
400-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
anes	NULL
2	NULL
and	NULL
3	NULL
and	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
,	NULL
200-	NULL
and	NULL
400-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
wild-type	NULL
PEBP2a	NULL
oligonucleotide	NULL
(	NULL
anes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
,	NULL
400-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
anes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
,	NULL
and	NULL
400-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
mutant	NULL
PEBP2	NULL
@	NULL
oligonucleotide	NULL
(	NULL
Zane	NULL
11	NULL
)	NULL
.	NULL

B	NULL
,	NULL
labeled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
anes	NULL
1-5	NULL
)	NULL
or	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
@	NULL
oligonucleotide	NULL
(	NULL
Zanes	NULL
6-10	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
ivt	NULL
AML-1B	NULL
protein	NULL
alone	NULL
(	NULL
Zanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
pl	NULL
of	NULL
a	NULL
preimmune	NULL
serum	NULL
(	NULL
Zanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
,	NULL
2	NULL
pl	NULL
of	NULL
the	NULL
anti-AML-1B	NULL
antiserum	NULL
(	NULL
Zanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
,	NULL
2	NULL
ul	NULL
of	NULL
the	NULL
anti-AML-1B	NULL
antiserum	NULL
,	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
corresponding	NULL
antigenic	NULL
peptide	NULL
(	NULL
Janes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
a	NULL
purified	NULL
anti-c-Myb	NULL
antibody	NULL
(	NULL
Zanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

S	NULL
194	NULL
B-cell	NULL
nuclear	NULL
extract	NULL
with	NULL
either	NULL
the	NULL
labeled	NULL
OSE2	NULL
oligonucleotide	NULL
or	NULL
the	NULL
labeled	NULL
PEBP2	NULL
@	NULL
oligonucleotide	NULL
migrated	NULL
at	NULL
the	NULL
same	NULL
location	NULL
as	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
and	NULL
any	NULL
of	NULL
these	NULL
two	NULL
probes	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
compare	NULL
lane	NULL
3	NULL
to	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
and	NULL
lane	NULL
8	NULL
to	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
the	NULL
difference	NULL
in	NULL
migration	NULL
observed	NULL
between	NULL
the	NULL
mouse	NULL
and	NULL
rat	NULL
osteoblast	NULL
nuclear	NULL
extracts-DNA	NULL
complexes	NULL
and	NULL
the	NULL
lymphocyte	NULL
nuclear	NULL
extracts-DNA	NULL
complexes	NULL
was	NULL
not	NULL
species	NULL
de-pendent	NULL
.	NULL

As	NULL
a	NULL
control	NULL
of	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
nuclear	NULL
extracts	NULL
Osteoblast-specific	NULL
Gene	NULL
Expression	NULL
,	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
Factors	NULL
used	NULL
we	NULL
showed	NULL
that	NULL
intact	NULL
Spl	NULL
binding	NULL
activity	NULL
was	NULL
present	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

The	NULL
Synthesis	NULL
of	NULL
OSF2	NULL
Is	NULL
Not	NULL
Inducible	NULL
by	NULL
Retinoic	NULL
Acid	NULL
Treatment	NULL
of	NULL
F9	NULL
or	NULL
ROS	NULL
17/2.8	NULL
Cells-The	NULL
PEBP2a	NULL
factors	NULL
are	NULL
not	NULL
detectable	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
untreated	NULL
F9	NULL
mouse	NULL
teratocarcinoma	NULL
cells	NULL
but	NULL
are	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
F9	NULL
cells	NULL
differentiated	NULL
by	NULL
a	NULL
5-day	NULL
treatment	NULL
with	NULL
RA	NULL
(	NULL
16	NULL
)	NULL
.	NULL

We	NULL
took	NULL
advantage	NULL
of	NULL
this	NULL
feature	NULL
of	NULL
the	NULL
PEBP2	NULL
«	NULL
@	NULL
factors	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
mobility	NULL
of	NULL
diffentiated	NULL
F9	NULL
nuclear	NULL
extracts-	NULL
DNA	NULL
complexes	NULL
was	NULL
identical	NULL
to	NULL
the	NULL
mobility	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extracts-DNA	NULL
complexes	NULL
in	NULL
GRA	NULL
.	NULL

We	NULL
generated	NULL
nuclear	NULL
extracts	NULL
of	NULL
F9	NULL
cells	NULL
either	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
RA	NULL
for	NULL
5	NULL
days	NULL
and	NULL
used	NULL
them	NULL
in	NULL
a	NULL
GRA	NULL
.	NULL

As	NULL
shown	NULL
previously	NULL
(	NULL
1	NULL
)	NULL
,	NULL
no	NULL
OSE2	NULL
binding	NULL
activity	NULL
was	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
untreated	NULL
F9	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

When	NULL
we	NULL
used	NULL
nuclear	NULL
extracts	NULL
of	NULL
RA-treated	NULL
cells	NULL
and	NULL
a	NULL
labeled	NULL
OSE2	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
GRA	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
complex	NULL
of	NULL
weak	NULL
intensity	NULL
that	NULL
had	NULL
a	NULL
mobility	NULL
similar	NULL
to	NULL
the	NULL
one	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
lymphocytes	NULL
nuclear	NULL
extracts	NULL
with	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
3	NULL
,	NULL
to	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
but	NULL
clearly	NULL
different	NULL
from	NULL
the	NULL
one	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
with	NULL
this	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

As	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
,	NULL
identical	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
we	NULL
used	NULL
the	NULL
labeled	NULL
PEBP2	NULL
«	NULL
@	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
also	NULL
used	NULL
nuclear	NULL
extracts	NULL
of	NULL
ROS	NULL
17/2.8	NULL
osteoblastic	NULL
cells	NULL
that	NULL
were	NULL
either	NULL
untreated	NULL
and	NULL
treated	NULL
with	NULL
RA	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
(	NULL
Zanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
treatment	NULL
of	NULL
ROS	NULL
17/2.8	NULL
with	NULL
RA	NULL
did	NULL
not	NULL
significantly	NULL
increase	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
already	NULL
existing	NULL
protein-DNA	NULL
complex	NULL
,	NULL
nor	NULL
did	NULL
it	NULL
generate	NULL
a	NULL
new	NULL
protein-DNA	NULL
complex	NULL
,	NULL
even	NULL
after	NULL
a	NULL
longer	NULL
exposure	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
this	NULL
experiment	NULL
confirms	NULL
that	NULL
the	NULL
synthesis	NULL
of	NULL
PEBP2	NULL
«	NULL
factors	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
F9	NULL
cells	NULL
treated	NULL
for	NULL
5	NULL
days	NULL
with	NULL
RA	NULL
,	NULL
but	NULL
it	NULL
also	NULL
indicates	NULL
that	NULL
the	NULL
synthesis	NULL
of	NULL
OSF2	NULL
is	NULL
not	NULL
up-regulated	NULL
by	NULL
RA	NULL
.	NULL

Thus	NULL
this	NULL
experiment	NULL
suggests	NULL
that	NULL
OSF2	NULL
may	NULL
be	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
PEBP2	NULL
@	NULL
/AML-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

AML-1B	NULL
Increases	NULL
mOG2	NULL
Promoter	NULL
Activity	NULL
through	NULL
Its	NULL
Binding	NULL
to	NULL
OSE2-To	NULL
determine	NULL
the	NULL
functional	NULL
relevance	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
AML-1B	NULL
to	NULL
OSE2	NULL
,	NULL
we	NULL
performed	NULL
DNA	NULL
cotransfection	NULL
experiments	NULL
.	NULL

For	NULL
this	NULL
assay	NULL
,	NULL
we	NULL
chose	NULL
the	NULL
mouse	NULL
cell	NULL
line	NULL
F9	NULL
,	NULL
because	NULL
it	NULL
does	NULL
not	NULL
express	NULL
either	NULL
osteocalcin	NULL
or	NULL
PEBP2	NULL
«	NULL
and	NULL
so	NULL
provides	NULL
a	NULL
null	NULL
background	NULL
.	NULL

We	NULL
used	NULL
three	NULL
different	NULL
expression	NULL
vectors	NULL
,	NULL
one	NULL
bearing	NULL
the	NULL
AML-1B	NULL
cDNA	NULL
in	NULL
the	NULL
correct	NULL
orientation	NULL
,	NULL
one	NULL
bearing	NULL
the	NULL
AML-1B	NULL
cDNA	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
(	NULL
both	NULL
driven	NULL
by	NULL
the	NULL
CMV	NULL
promoter	NULL
)	NULL
,	NULL
and	NULL
one	NULL
bearing	NULL
the	NULL
c-Myb	NULL
cDNA	NULL
in	NULL
the	NULL
correct	NULL
orientation	NULL
driven	NULL
by	NULL
the	NULL
DHFR	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

The	NULL
reporter	NULL
plasmids	NULL
we	NULL
used	NULL
contained	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
luciferase	NULL
(	NULL
luc	NULL
)	NULL
gene	NULL
driven	NULL
by	NULL
a	NULL
-34/+13	NULL
mOG2	NULL
promoter	NULL
fragment	NULL
that	NULL
has	NULL
no	NULL
transcriptional	NULL
activity	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Upstream	NULL
of	NULL
this	NULL
promoter	NULL
,	NULL
we	NULL
cloned	NULL
six	NULL
copies	NULL
of	NULL
a	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
p6OSE2Z-luc	NULL
)	NULL
,	NULL
six	NULL
copies	NULL
of	NULL
a	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
p6OSE2	NULL
m-luc	NULL
)	NULL
,	NULL
or	NULL
six	NULL
copies	NULL
of	NULL
a	NULL
wild-type	NULL
OSE1	NULL
oligonucleotide	NULL
,	NULL
the	NULL
other	NULL
osteoblast-specific	NULL
cis-acting	NULL
element	NULL
present	NULL
in	NULL
the	NULL
mO0G2	NULL
promoter	NULL
(	NULL
p6OSE1-lue	NULL
)	NULL
(	NULL
1	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
luc	NULL
activity	NULL
were	NULL
detected	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
minimal	NULL
-34/+13	NULL
mOG2	NULL
promoter	NULL
or	NULL
p6OSE2Z-lue	NULL
alone	NULL
,	NULL
whereas	NULL
cotransfection	NULL
of	NULL
the	NULL
p6OSE2-luc	NULL
reporter	NULL
plasmid	NULL
along	NULL
with	NULL
the	NULL
AML-1B	NULL
cDNA	NULL
cloned	NULL
in	NULL
the	NULL
correct	NULL
orientation	NULL
stimulated	NULL
lue	NULL
expression	NULL
200-fold	NULL
.	NULL

To	NULL
demonstrate	NULL
the	NULL
specificity	NULL
of	NULL
this	NULL
effect	NULL
,	NULL
we	NULL
performed	NULL
several	NULL
control	NULL
experiments	NULL
.	NULL

First	NULL
,	NULL
no	NULL
stimulation	NULL
occurred	NULL
when	NULL
we	NULL
used	NULL
the	NULL
expression	NULL
vector	NULL
containing	NULL
AML-1B	NULL
cDNA	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
pG6OSE2	NULL
m-luc	NULL
reporter	NULL
plasmid	NULL
was	NULL
unaffected	NULL
by	NULL
cotransfection	NULL
with	NULL
CMV-AML-1B	NULL
fusion	NULL
gene	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
p6OSE1-lue	NULL
reporter	NULL
plasmid	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Osteoblast-specific	NULL
Gene	NULL
Expression	NULL
,	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
Factors	NULL
I	NULL
anti-	NULL
AML-1B	NULL
antiserum	NULL
(	NULL
l	NULL
)	NULL
-	NULL
0	NULL
_	NULL
2	NULL
AML-1B	NULL
antigenic	NULL
peptide	NULL
anti-c-myb	NULL
antibody	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Abolition	NULL
of	NULL
OSF2	NULL
binding	NULL
to	NULL
DNA	NULL
by	NULL
an	NULL
anti-AML-1B	NULL
antiserum	NULL
.	NULL

DNA	NULL
binding	NULL
was	NULL
analyzed	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

Labeled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
either	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
(	NULL
Zanes	NULL
1-9	NULL
)	NULL
or	NULL
mouse	NULL
primary	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
(	NULL
Zanes	NULL
10-18	NULL
)	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
anti-AML-1B	NULL
antiserum	NULL
(	NULL
Zanes	NULL
1	NULL
,	NULL
6	NULL
,	NULL
10	NULL
,	NULL
and	NULL
15	NULL
)	NULL
,	NULL
in	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
the	NULL
anti-AML-1B	NULL
antiserum	NULL
alone	NULL
(	NULL
lanes	NULL
2-5	NULL
,	NULL
7	NULL
,	NULL
11-14	NULL
,	NULL
and	NULL
16	NULL
)	NULL
,	NULL
in	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
anti-AML-1B	NULL
antiserum	NULL
and	NULL
the	NULL
AML-1B	NULL
antigenic	NULL
peptide	NULL
(	NULL
12	NULL
ug	NULL
,	NULL
lane	NULL
8	NULL
,	NULL
and	NULL
7	NULL
ug	NULL
,	NULL
lane	NULL
17	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
a	NULL
purified	NULL
anti-c-Myb	NULL
antibody	NULL
(	NULL
1	NULL
pl	NULL
)	NULL
(	NULL
Zanes	NULL
9	NULL
and	NULL
18	NULL
)	NULL
.	NULL

Incubation	NULL
conditions	NULL
were	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
30977	NULL
Mouse	NULL
primary	NULL
osteoblasts	NULL
nuclear	NULL
extracts	NULL
3	NULL
0	NULL
40	NULL
5	NULL
0	NULL
50	NULL
50	NULL
0	NULL
00	NULL
2	NULL
3	NULL
4	NULL
S	NULL
0	NULL
3	NULL
3	NULL
0	NULL
aus	NULL
.	NULL

is	NULL
het	NULL
bod	NULL
bg	NULL
10	NULL
2	NULL
%	NULL
3	NULL
4	NULL
A	NULL
B	NULL
»	NULL
C	NULL
3	NULL
§	NULL
N	NULL
a	NULL
£	NULL
~	NULL
a	NULL
is	NULL
5	NULL
=	NULL
3	NULL
a	NULL
Fa	NULL
t	NULL
a	NULL
-	NULL
3	NULL
a	NULL
a	NULL
»	NULL
§	NULL
4	NULL
a	NULL
£	NULL
§	NULL
&	NULL
§	NULL
a	NULL
&	NULL
€	NULL
=	NULL
300	NULL
=	NULL
yo	NULL
&	NULL
p	NULL
3	NULL
?	NULL

a	NULL
$	NULL
&	NULL
aoop	NULL
$	NULL
o	NULL
p	NULL
$	NULL
$	NULL
&	NULL
yo	NULL
£	NULL
6	NULL
©	NULL
a	NULL
80	NULL
60x	NULL
&	NULL
&	NULL
§	NULL
A	NULL
§	NULL
R	NULL
no	NULL
£0	NULL
&	NULL
#	NULL
o	NULL
g	NULL
§	NULL
R	NULL
e	NULL
fia	NULL
:	NULL
riiac	NULL
:	NULL
:	NULL
o	NULL
ffi	NULL
PFP	NULL
o	NULL
f	NULL
7	NULL
T	NULL
:	NULL
o	NULL
&	NULL
<	NULL
<	NULL
p	NULL
£	NULL
3	NULL
a	NULL
$	NULL
Fos	NULL
$	NULL
8	NULL
$	NULL
f	NULL
$	NULL
F	NULL
go	NULL
F	NULL
5g	NULL
$	NULL
b	NULL
$	NULL
¢	NULL
i	NULL
4	NULL
a	NULL
35	NULL
4	NULL
io	NULL
&	NULL
a	NULL
4	NULL
4	NULL
&	NULL
Jo	NULL
&	NULL
J	NULL
&	NULL
io	NULL
&	NULL
%	NULL
E	NULL
4	NULL
S	NULL
x	NULL
to	NULL
``	NULL
u	NULL
.	NULL

-	NULL
inf	NULL
i1	NULL
be	NULL
___	NULL
=	NULL
as	NULL
as	NULL
f	NULL
NU	NULL
»	NULL
tort	NULL
i-	NULL
ta	NULL
®	NULL
me	NULL
bk	NULL
«	NULL
|___	NULL
``	NULL
we	NULL
10	NULL
%	NULL
3	NULL
40	NULL
5	NULL
6	NULL
70	NULL
8	NULL
9	NULL
10	NULL
2	NULL
3	NULL
4	NULL
5	NULL
IO2	NULL
3	NULL
40	NULL
50	NULL
6	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

OSF2-DNA	NULL
complex	NULL
has	NULL
a	NULL
different	NULL
mobility	NULL
than	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
DNA-complexes	NULL
.	NULL

DNA	NULL
binding	NULL
was	NULL
assayed	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

A	NULL
,	NULL
labeled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
Zanes	NULL
1-5	NULL
)	NULL
or	NULL
labeled	NULL
wild-type	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
(	NULL
Zanes	NULL
6-10	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
of	NULL
nonmineralizing	NULL
mouse	NULL
primary	NULL
osteoblasts	NULL
(	NULL
Zanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
,	NULL
of	NULL
ROS	NULL
17/2.8	NULL
(	NULL
Zanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
,	NULL
of	NULL
S	NULL
194	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
,	NULL
of	NULL
Molt	NULL
4	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
,	NULL
and	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
long	NULL
arrow	NULL
denotes	NULL
the	NULL
OSF2-DNA	NULL
complex	NULL
,	NULL
the	NULL
shorter	NULL
arrow	NULL
denotes	NULL
the	NULL
lymphocyte	NULL
nuclear	NULL
extracts-DNA	NULL
complex	NULL
.	NULL

B	NULL
,	NULL
labeled	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
of	NULL
ROS	NULL
17/2.8	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
,	NULL
of	NULL
untreated	NULL
F9	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
of	NULL
RA-treated	NULL
F9	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
and	NULL
of	NULL
untreated	NULL
(	NULL
ane	NULL
4	NULL
)	NULL
or	NULL
RA-treated	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
ROS	NULL
17/2.8	NULL
cells	NULL
.	NULL

The	NULL
retinoic	NULL
acid	NULL
treatment	NULL
and	NULL
incubation	NULL
conditions	NULL
were	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

C	NULL
,	NULL
labeled	NULL
Sp1	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
either	NULL
nuclear	NULL
extracts	NULL
of	NULL
nonmineralizing	NULL
mouse	NULL
primary	NULL
osteoblasts	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
,	NULL
of	NULL
ROS	NULL
17/2.8	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
of	NULL
Molt	NULL
4	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
,	NULL
of	NULL
Jurkat	NULL
(	NULL
ane	NULL
4	NULL
)	NULL
,	NULL
of	NULL
untreated	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
RA-treated	NULL
F9	NULL
cells	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

cotransfection	NULL
with	NULL
CMV-AML-1B	NULL
fusion	NULL
gene	NULL
.	NULL

Lastly	NULL
,	NULL
an	NULL
expression	NULL
vector	NULL
containing	NULL
the	NULL
cDNA	NULL
and	NULL
coding	NULL
another	NULL
myeloid-specific	NULL
transcription	NULL
factor	NULL
,	NULL
c-Myb	NULL
,	NULL
did	NULL
not	NULL
induce	NULL
any	NULL
increase	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
p6OSE2-lue	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
results	NULL
establish	NULL
that	NULL
AML-1B	NULL
is	NULL
capable	NULL
of	NULL
increasing	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
short	NULL
m0OG2	NULL
promoter	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
OSE2	NULL
and	NULL
that	NULL
this	NULL
effect	NULL
is	NULL
specific	NULL
.	NULL

DISCUSSION	NULL
The	NULL
results	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
a	NULL
member	NULL
of	NULL
the	NULL
PEBP2	NULL
@	NULL
/AML-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
can	NULL
activate	NULL
mOG2	NULL
expression	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
OSE2	NULL
,	NULL
an	NULL
osteoblast-specific	NULL
cis-acting	NULL
element	NULL
(	NULL
1	NULL
)	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
based	NULL
on	NULL
several	NULL
experimental	NULL
arguments	NULL
.	NULL

First	NULL
,	NULL
OSE2	NULL
contains	NULL
a	NULL
sequence	NULL
identical	NULL
to	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
factors	NULL
.	NULL

Second	NULL
,	NULL
an	NULL
ivt	NULL
AML-1B	NULL
binds	NULL
specifically	NULL
to	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
OSE2	NULL
sequence	NULL
.	NULL

Third	NULL
,	NULL
an	NULL
antibody	NULL
recognizing	NULL
several	NULL
members	NULL
of	NULL
the	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
greatly	NULL
decreases	NULL
or	NULL
abolishes	NULL
the	NULL
binding	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
.	NULL

Finally	NULL
,	NULL
in	NULL
DNA	NULL
cotrans-	NULL
fection	NULL
experiments	NULL
an	NULL
expression	NULL
vector	NULL
containing	NULL
AML-1B	NULL
cDNA	NULL
,	NULL
the	NULL
human	NULL
homologue	NULL
of	NULL
the	NULL
murine	NULL
PEBP2	NULL
«	NULL
B	NULL
,	NULL
increases	NULL
activity	NULL
of	NULL
a	NULL
short	NULL
osteocalcin	NULL
promoter	NULL
through	NULL
mul-timers	NULL
of	NULL
OSE2	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
suggest	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
recombinant	NULL
AML-1B	NULL
to	NULL
OSE2Z	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
m0OG2	NULL
promoter	NULL
by	NULL
this	NULL
factor	NULL
are	NULL
specific	NULL
.	NULL

An	NULL
antibody	NULL
directed	NULL
against	NULL
another	NULL
transcription	NULL
factor	NULL
did	NULL
not	NULL
alter	NULL
binding	NULL
of	NULL
ROS	NULL
17/2.8	NULL
nuclear	NULL
extracts	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
.	NULL

When	NULL
we	NULL
used	NULL
other	NULL
ivt	NULL
transcription	NULL
factors	NULL
as	NULL
control	NULL
in	NULL
GRA	NULL
,	NULL
they	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Most	NULL
im-portantly	NULL
,	NULL
in	NULL
DNA	NULL
cotransfection	NULL
experiments	NULL
in	NULL
F9	NULL
cells	NULL
,	NULL
which	NULL
express	NULL
neither	NULL
the	NULL
osteocalcin	NULL
genes	NULL
nor	NULL
the	NULL
PEBP2	NULL
«	NULL
genes	NULL
,	NULL
AML-1B	NULL
,	NULL
dramatically	NULL
increased	NULL
(	NULL
200-fold	NULL
)	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
minimum	NULL
mOG2	NULL
promoter	NULL
bearing	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
a	NULL
promoter	NULL
bearing	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
or	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
OSE1	NULL
oligonucleotide	NULL
,	NULL
the	NULL
other	NULL
osteoblast-specific	NULL
cis-acting	NULL
element	NULL
present	NULL
in	NULL
the	NULL
m0G2	NULL
pro	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
30978	NULL
A	NULL
correct	NULL
Expression	NULL
vectors	NULL
-	NULL
pCMV-AML~IB	NULL
AML-1B	NULL
|	NULL
|	NULL
orientation	NULL
pCMVv-gT-7wy	NULL
am	NULL
|	NULL
ariny	NULL
]	NULL
[	NULL
Bs	NULL
.	NULL

___Gix_Lemb	NULL
]	NULL
.z	NULL
orientation	NULL
pMbMIDHER	NULL
Reporter	NULL
plasmids	NULL
_	NULL
p34-luc	NULL
p6OSE2-lue	NULL
$	NULL
y	NULL
OSE	NULL
p6OSE2m-luc	NULL
6	NULL
mut	NULL
Ose2	NULL
p6OSEL-lue	NULL
6	NULL
w	NULL
OSEL	NULL
Reporter	NULL
Expression	NULL
Fold	NULL
induction	NULL
plasmid	NULL
vector	NULL
5.0	NULL
1	NULL
(	NULL
|	NULL
)	NULL
0	NULL
1	NULL
?	NULL

0	NULL
2	NULL
(	NULL
|	NULL
)	NULL
0	NULL
p34-luc	NULL
=	NULL
pCMV-AML~1B	NULL
p6OSE2-lue	NULL
=	NULL
pCMV-AML-1B	NULL
pMbMIDHFR	NULL
p6OSE2m-luc	NULL
pCMV-AML-1B	NULL
pCMV-II-TWY	NULL
pMbMIDHFR	NULL
P6OSE1	NULL
-luc	NULL
pCMV-AML-LB	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

AML-1B	NULL
activates	NULL
transcription	NULL
of	NULL
the	NULL
osteocalcin	NULL
promoter	NULL
in	NULL
F9	NULL
cells	NULL
through	NULL
OSE2	NULL
.	NULL

A	NULL
,	NULL
representation	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
and	NULL
reporter	NULL
plasmids	NULL
.	NULL

Expression	NULL
vectors	NULL
,	NULL
pCMV-AML-1B	NULL
sense	NULL
:	NULL
the	NULL
AML-1B	NULL
cDNA	NULL
was	NULL
cloned	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
in	NULL
the	NULL
correct	NULL
orientation	NULL
;	NULL
pCMV-AML-1B	NULL
antisense	NULL
:	NULL
the	NULL
AML-1B	NULL
cDNA	NULL
was	NULL
cloned	NULL
downstream	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
;	NULL
pMbMI/DHFR	NULL
:	NULL
the	NULL
c-Myb	NULL
cDNA	NULL
was	NULL
cloned	NULL
downstream	NULL
of	NULL
the	NULL
DHFR	NULL
promoter	NULL
in	NULL
the	NULL
correct	NULL
orientation	NULL
.	NULL

Reporter	NULL
plasmids	NULL
,	NULL
all	NULL
the	NULL
reporter	NULL
plasmids	NULL
contain	NULL
the	NULL
-34/+13	NULL
mOG2	NULL
promoter-luciferase	NULL
fusion	NULL
gene	NULL
.	NULL

p6OSE2-lue	NULL
contains	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
OSE2	NULL
oligonucleotide	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
-34/+13	NULL
mOG2	NULL
promoter	NULL
.	NULL

p6OSE2	NULL
m-lue	NULL
contains	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
mutant	NULL
OSE2	NULL
oligonucleotide	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
-34/+13	NULL
mOG2	NULL
promoter	NULL
.	NULL

pGOSE/-lue	NULL
contains	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
OSE1	NULL
oligonucleotide	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
-34/+13	NULL
mOG2	NULL
promoter	NULL
.	NULL

B	NULL
,	NULL
F9	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
expression	NULL
vector	NULL
.	NULL

Values	NULL
are	NULL
expressed	NULL
relatively	NULL
to	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
p6OSE2-lue	NULL
,	NULL
which	NULL
was	NULL
set	NULL
at	NULL
1	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
results	NULL
3-6	NULL
independent	NULL
transfection	NULL
experiments	NULL
.	NULL

moter	NULL
.	NULL

In	NULL
this	NULL
assay	NULL
,	NULL
c-Myb	NULL
,	NULL
another	NULL
myeloid-specific	NULL
transcription	NULL
factor	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
p6OSE2-luc	NULL
level	NULL
of	NULL
expression	NULL
,	NULL
further	NULL
demonstrating	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
AML-1B	NULL
effect	NULL
.	NULL

The	NULL
murine	NULL
transcription	NULL
factor	NULL
PEBP2	NULL
was	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
polyomavirus	NULL
core	NULL
enhancer	NULL
(	NULL
23	NULL
)	NULL
.	NULL

It	NULL
is	NULL
composed	NULL
of	NULL
two	NULL
distinct	NULL
peptides	NULL
,	NULL
PEBP2	NULL
«	NULL
and	NULL
PEBP2	NULL
$	NULL
(	NULL
11	NULL
)	NULL
.	NULL

To	NULL
date	NULL
two	NULL
distinct	NULL
PEBP2	NULL
«	NULL
factors	NULL
,	NULL
encoded	NULL
by	NULL
two	NULL
distinct	NULL
genes	NULL
,	NULL
have	NULL
been	NULL
identified	NULL
:	NULL
PEBP2	NULL
«	NULL
A	NULL
,	NULL
and	NULL
PEBP2	NULL
@	NULL
B	NULL
.	NULL

The	NULL
two	NULL
PEBP2	NULL
«	NULL
@	NULL
factors	NULL
have	NULL
in	NULL
common	NULL
a	NULL
DNA-binding	NULL
domain	NULL
highly	NULL
homologous	NULL
to	NULL
the	NULL
DNA-binding	NULL
domain	NULL
of	NULL
runt	NULL
,	NULL
a	NULL
segmentation	NULL
gene	NULL
in	NULL
Drosophila	NULL
.	NULL

This	NULL
runt	NULL
domain	NULL
also	NULL
allows	NULL
the	NULL
PEBP2	NULL
«	NULL
proteins	NULL
to	NULL
dimerize	NULL
with	NULL
PEBP2f	NULL
,	NULL
a	NULL
ubiquitously	NULL
expressed	NULL
nuclear	NULL
factor	NULL
that	NULL
itself	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
DNA	NULL
but	NULL
does	NULL
increase	NULL
the	NULL
affinity	NULL
of	NULL
PEBP2	NULL
«	NULL
factors	NULL
for	NULL
their	NULL
binding	NULL
sites	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
two	NULL
genes	NULL
PEBP2eA	NULL
and	NULL
PEBP2	NULL
@	NULL
B	NULL
have	NULL
a	NULL
different	NULL
pattern	NULL
of	NULL
expression	NULL
:	NULL
PEBP2	NULL
«	NULL
A	NULL
is	NULL
expressed	NULL
in	NULL
T-cells	NULL
(	NULL
7	NULL
)	NULL
,	NULL
PEBP2	NULL
«	NULL
B	NULL
is	NULL
expressed	NULL
in	NULL
lung	NULL
and	NULL
pre	NULL
B-cells	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
T-cells	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Three	NULL
human	NULL
homo-	NULL
Osteoblast-specific	NULL
Gene	NULL
Expression	NULL
,	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
Factors	NULL
logues	NULL
of	NULL
PEBP2	NULL
«	NULL
,	NULL
AML-1A	NULL
,	NULL
and	NULL
AML-1B	NULL
and	NULL
PEBP2ac	NULL
,	NULL
have	NULL
been	NULL
characterized	NULL
recently	NULL
.	NULL

AML-1A	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
break-point	NULL
on	NULL
chromosome	NULL
21	NULL
(	NULL
t	NULL
(	NULL
8	NULL
;	NULL
21	NULL
)	NULL
)	NULL
present	NULL
in	NULL
a	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
(	NULL
24	NULL
)	NULL
,	NULL
AML-1B	NULL
was	NULL
cloned	NULL
in	NULL
a	NULL
B-lymphocyte	NULL
cDNA	NULL
library	NULL
(	NULL
5	NULL
)	NULL
,	NULL
and	NULL
PEBP2ac	NULL
is	NULL
largely	NULL
distributed	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
most	NULL
important	NULL
question	NULL
raised	NULL
by	NULL
the	NULL
present	NULL
study	NULL
is	NULL
whether	NULL
OSF2	NULL
,	NULL
the	NULL
factor	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
and	NULL
binding	NULL
to	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
,	NULL
is	NULL
an	NULL
already	NULL
known	NULL
PEBP2	NULL
«	NULL
factor	NULL
or	NULL
a	NULL
new	NULL
but	NULL
biochemically	NULL
and	NULL
immunologically	NULL
related	NULL
factor	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
either	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
or	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
,	NULL
with	NULL
OSE2	NULL
oligonucleotide	NULL
have	NULL
a	NULL
different	NULL
mobility	NULL
in	NULL
GRA	NULL
.	NULL

We	NULL
obtained	NULL
identical	NULL
results	NULL
when	NULL
using	NULL
PEBP2	NULL
«	NULL
oligonucleotide	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
of	NULL
PEBP2	NULL
«	NULL
A	NULL
and	NULL
PEBP2	NULL
«	NULL
B	NULL
patterns	NULL
of	NULL
expression	NULL
during	NULL
mouse	NULL
development	NULL
did	NULL
not	NULL
mention	NULL
that	NULL
either	NULL
of	NULL
these	NULL
two	NULL
genes	NULL
are	NULL
expressed	NULL
in	NULL
developing	NULL
skeleton	NULL
(	NULL
25	NULL
)	NULL
.	NULL

This	NULL
report	NULL
also	NULL
mentioned	NULL
that	NULL
PEBP2	NULL
«	NULL
B	NULL
transcripts	NULL
were	NULL
abundant	NULL
in	NULL
lung	NULL
,	NULL
a	NULL
tissue	NULL
that	NULL
has	NULL
no	NULL
detectable	NULL
OSE2Z	NULL
binding	NULL
activity	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Lastly	NULL
,	NULL
the	NULL
disruption	NULL
of	NULL
the	NULL
human	NULL
homologue	NULL
of	NULL
PEBP2	NULL
«	NULL
B	NULL
,	NULL
AML-1A	NULL
,	NULL
is	NULL
associated	NULL
with	NULL
myeloid	NULL
leukemia	NULL
but	NULL
not	NULL
with	NULL
skeletal	NULL
abnormalities	NULL
(	NULL
24	NULL
)	NULL
.	NULL

These	NULL
three	NULL
indirect	NULL
lines	NULL
of	NULL
evidence	NULL
suggest	NULL
that	NULL
OSF2	NULL
,	NULL
the	NULL
factor	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
and	NULL
binding	NULL
to	NULL
OSE2	NULL
,	NULL
is	NULL
different	NULL
from	NULL
the	NULL
previously	NULL
described	NULL
PEBP2	NULL
«	NULL
factors	NULL
.	NULL

More	NULL
compelling	NULL
although	NULL
still	NULL
indirect	NULL
evidence	NULL
suggesting	NULL
that	NULL
OSF2	NULL
is	NULL
a	NULL
previously	NULL
undescribed	NULL
PEBP2	NULL
«	NULL
factor	NULL
comes	NULL
from	NULL
our	NULL
experiments	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
RA-treated	NULL
F9	NULL
or	NULL
ROS	NULL
17/2.8	NULL
cells	NULL
.	NULL

This	NULL
treatment	NULL
increased	NULL
only	NULL
the	NULL
synthesis	NULL
of	NULL
PEBP2	NULL
«	NULL
@	NULL
factors	NULL
that	NULL
form	NULL
protein-DNA	NULL
complexes	NULL
of	NULL
a	NULL
faster	NULL
mobility	NULL
when	NULL
incubated	NULL
with	NULL
the	NULL
OSE2	NULL
oligonucleotide	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
protein-DNA	NULL
complex	NULL
formed	NULL
upon	NULL
incubation	NULL
of	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
with	NULL
this	NULL
oligonucleotide	NULL
.	NULL

The	NULL
synthesis	NULL
of	NULL
OSF2	NULL
itself	NULL
could	NULL
not	NULL
be	NULL
up-regulated	NULL
by	NULL
RA	NULL
using	NULL
the	NULL
same	NULL
treatment	NULL
conditions	NULL
.	NULL

We	NULL
are	NULL
fully	NULL
aware	NULL
that	NULL
this	NULL
experimental	NULL
evidence	NULL
is	NULL
indi-rect	NULL
;	NULL
a	NULL
definite	NULL
proof	NULL
of	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
PEBP2	NULL
«	NULL
w-related	NULL
factor	NULL
binding	NULL
to	NULL
OSE2	NULL
will	NULL
have	NULL
to	NULL
await	NULL
the	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
OSF2	NULL
and	NULL
PEBP2	NULL
«	NULL
cDNAs	NULL
from	NULL
osteoblastic	NULL
cDNA	NULL
libraries	NULL
.	NULL

If	NULL
OSF2	NULL
is	NULL
one	NULL
of	NULL
the	NULL
three	NULL
described	NULL
PEBP2	NULL
«	NULL
factors	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
it	NULL
affects	NULL
osteoblast	NULL
differentiation	NULL
alone	NULL
or	NULL
in	NULL
association	NULL
with	NULL
other	NULL
factors	NULL
will	NULL
have	NULL
to	NULL
be	NULL
investigated	NULL
in	NULL
great	NULL
detail	NULL
because	NULL
the	NULL
osteocalcin	NULL
genes	NULL
are	NULL
not	NULL
expressed	NULL
in	NULL
lymphoid	NULL
tissues	NULL
.	NULL

Besides	NULL
the	NULL
osteoblast-specific	NULL
cis-acting	NULL
elements	NULL
we	NULL
identified	NULL
in	NULL
the	NULL
m0G2	NULL
promoter	NULL
,	NULL
several	NULL
regions	NULL
of	NULL
various	NULL
genes	NULL
expressed	NULL
in	NULL
osteoblasts	NULL
have	NULL
been	NULL
recognized	NULL
recently	NULL
as	NULL
containing	NULL
osteoblast-specific	NULL
cis-acting	NULL
elements	NULL
.	NULL

In	NULL
the	NULL
osteocalcin	NULL
promoter	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
homeodomain	NULL
containing	NULL
proteins	NULL
MSX1	NULL
and	NULL
MSX2	NULL
has	NULL
been	NULL
identified	NULL
(	NULL
26	NULL
)	NULL
,	NULL
although	NULL
the	NULL
role	NULL
of	NULL
the	NULL
MSX	NULL
proteins	NULL
in	NULL
regulating	NULL
osteocalcin	NULL
gene	NULL
expression	NULL
is	NULL
unclear	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Using	NULL
a	NULL
transgenic	NULL
mouse	NULL
approach	NULL
Pavlin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
28	NULL
)	NULL
have	NULL
identified	NULL
a	NULL
region	NULL
of	NULL
the	NULL
rat	NULL
a1	NULL
(	NULL
I	NULL
)	NULL
collagen	NULL
promoter	NULL
required	NULL
for	NULL
osteoblast-specific	NULL
expression	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
in	NULL
vivo	NULL
.	NULL

This	NULL
region	NULL
is	NULL
centered	NULL
by	NULL
a	NULL
typical	NULL
binding	NULL
site	NULL
for	NULL
a	NULL
homeodomain-containing	NULL
protein	NULL
and	NULL
does	NULL
not	NULL
contain	NULL
any	NULL
obvious	NULL
PEBP2	NULL
«	NULL
binding	NULL
site	NULL
.	NULL

The	NULL
type	NULL
I	NULL
collagen	NULL
genes	NULL
are	NULL
expressed	NULL
early	NULL
during	NULL
osteoblast	NULL
differentiation	NULL
,	NULL
whereas	NULL
the	NULL
osteocalcin	NULL
genes	NULL
are	NULL
late	NULL
markers	NULL
of	NULL
osteoblast	NULL
differentiation	NULL
.	NULL

Given	NULL
these	NULL
different	NULL
temporal	NULL
patterns	NULL
of	NULL
expression	NULL
,	NULL
it	NULL
is	NULL
not	NULL
surprising	NULL
that	NULL
different	NULL
osteoblast-specific	NULL
cis-acting	NULL
elements	NULL
and	NULL
trans-acting	NULL
factors	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
osteocalcin	NULL
genes	NULL
and	NULL
the	NULL
type	NULL
I	NULL
collagen	NULL
genes	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
have	NULL
presented	NULL
evidence	NULL
that	NULL
AML-1B	NULL
binds	NULL
specifically	NULL
to	NULL
OSE2	NULL
,	NULL
an	NULL
osteoblast-specific	NULL
cis-acting	NULL
element	NULL
,	NULL
and	NULL
increases	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
short	NULL
m0OG2	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Osteoblast-specific	NULL
Gene	NULL
Expression	NULL
,	NULL
PEBP2	NULL
«	NULL
/AML-1	NULL
Factors	NULL
promoter	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
OSE2	NULL
.	NULL

This	NULL
study	NULL
also	NULL
shows	NULL
that	NULL
OSF2	NULL
,	NULL
the	NULL
factor	NULL
present	NULL
in	NULL
osteoblast	NULL
nuclear	NULL
extracts	NULL
and	NULL
binding	NULL
to	NULL
OSE2	NULL
,	NULL
has	NULL
different	NULL
characteristics	NULL
than	NULL
the	NULL
already	NULL
described	NULL
PEBP2	NULL
«	NULL
factors	NULL
.	NULL

The	NULL
precise	NULL
identity	NULL
of	NULL
OSF2	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
the	NULL
known	NULL
PEBP2	NULL
@	NULL
factors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
its	NULL
activation	NULL
of	NULL
the	NULL
osteocalcin	NULL
gene	NULL
expression	NULL
,	NULL
are	NULL
currently	NULL
under	NULL
investigation	NULL
.	NULL

Acknowledgments-We	NULL
are	NULL
very	NULL
grateful	NULL
to	NULL
Drs	NULL
.	NULL

Meyers	NULL
and	NULL
Hiebert	NULL
(	NULL
St.	NULL
Jude	NULL
Children	NULL
's	NULL
Research	NULL
Hospital	NULL
,	NULL
Memphis	NULL
,	NULL
TN	NULL
)	NULL
,	NULL
who	NULL
generously	NULL
provided	NULL
us	NULL
with	NULL
reagents	NULL
that	NULL
made	NULL
this	NULL
study	NULL
possible	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dr.	NULL
B.	NULL
Calabreta	NULL
(	NULL
Jefferson	NULL
Cancer	NULL
Institute	NULL
,	NULL
Thomas	NULL
Jefferson	NULL
University	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
)	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
the	NULL
expression	NULL
vector	NULL
pMbMI/DHEFR	NULL
.	NULL

REFERENCES	NULL
.	NULL

Ducy	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Karsenty	NULL
,	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
1858-1869	NULL
2	NULL
.	NULL

Hauschka	NULL
,	NULL
P.	NULL
V.	NULL
,	NULL
Lian	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Cole	NULL
,	NULL
D.	NULL
E.	NULL
C.	NULL
,	NULL
and	NULL
Gundberg	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Physiol	NULL
.	NULL

Rev	NULL
.	NULL

69	NULL
,	NULL
990-1047	NULL
.	NULL

Boulikas	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Crit	NULL
.	NULL

Rev	NULL
.	NULL

Eukacaryotic	NULL
Gene	NULL
Expression	NULL
4	NULL
,	NULL
117-321	NULL
.	NULL

Meyers	NULL
,	NULL
S.	NULL
,	NULL
Downing	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
6336-6345	NULL
.	NULL

Meyers	NULL
,	NULL
S.	NULL
,	NULL
Lenny	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
1974-1982	NULL
6	NULL
.	NULL

Bae	NULL
,	NULL
S.-C.	NULL
,	NULL
Yamaguchi-Iwai	NULL
,	NULL
Y.	NULL
,	NULL
Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Inuzuka	NULL
,	NULL
M.	NULL
,	NULL
Kagoshima	NULL
,	NULL
H.	NULL
,	NULL
Shigesada	NULL
,	NULL
K.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Oncogene	NULL
8	NULL
,	NULL
809-814	NULL
7	NULL
.	NULL

Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Kagoshima	NULL
,	NULL
H.	NULL
,	NULL
Inuzuka	NULL
,	NULL
M.	NULL
,	NULL
Lu	NULL
,	NULL
J.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
Shigesada	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
6859-6863	NULL
8	NULL
.	NULL

Bae	NULL
,	NULL
S.-C.	NULL
,	NULL
Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Oka	NULL
,	NULL
H.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
Shigesada	NULL
,	NULL
K.	NULL
,	NULL
Jenkins	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Gilbert	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Copeland	NULL
,	NULL
N.	NULL
G.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
3242-3252	NULL
9	NULL
.	NULL

Bae	NULL
,	NULL
S.-C.	NULL
,	NULL
Takahashi	NULL
,	NULL
E.-L.	NULL
,	NULL
Zhang	NULL
,	NULL
Y.	NULL
W.	NULL
,	NULL
Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Shigesada	NULL
,	NULL
K.	NULL
,	NULL
Namba	NULL
,	NULL
a	NULL
p	NULL
to	NULL
u	NULL
10	NULL
11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

30979	NULL
Y.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Gene	NULL
(	NULL
Amst	NULL
.	NULL
)	NULL

159	NULL
,	NULL
245-248	NULL
.	NULL

Kania	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Bonner	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Duffy	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Gergen	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

4	NULL
,	NULL
1701-1713	NULL
Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Inuzuka	NULL
,	NULL
M.	NULL
,	NULL
Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
Naito-Fujimoto	NULL
,	NULL
M.	NULL
,	NULL
Ito	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Shigesada	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Virology	NULL
194	NULL
,	NULL
314-331	NULL
Nuchprayoon	NULL
,	NULL
I.	NULL
,	NULL
Meyers	NULL
,	NULL
S.	NULL
,	NULL
Scott	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Suzow	NULL
,	NULL
J.	NULL
,	NULL
Hiebert	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Friedman	NULL
,	NULL
A.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
5558-5568	NULL
Giese	NULL
,	NULL
K.	NULL
,	NULL
Kingsley	NULL
,	NULL
C.	NULL
,	NULL
Kirshner	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
Grossched	NULL
]	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
995-1008	NULL
Zhang	NULL
,	NULL
D.-E.	NULL
,	NULL
Fujioka	NULL
,	NULL
K.-L.	NULL
,	NULL
Hetherington	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Shapiro	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Chen	NULL
,	NULL
H.-M.	NULL
,	NULL
Look	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
and	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
8085-8095	NULL
Chen	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Okayama	NULL
,	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
2745-2752	NULL
Furukawa	NULL
,	NULL
K.	NULL
,	NULL
Yamaguchi	NULL
,	NULL
Y.	NULL
,	NULL
Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Shigesada	NULL
,	NULL
K.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
Growth	NULL
&	NULL
Differ	NULL
.	NULL

1	NULL
,	NULL
135-147	NULL
Clarke	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Kukowska-Latallo	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Westin	NULL
,	NULL
E.	NULL
,	NULL
Smith	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Prochownik	NULL
,	NULL
E.	NULL
V.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
884-892	NULL
Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebowitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Muller	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
6419	NULL
Wang	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Speck	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
89-102	NULL
Gidoni	NULL
,	NULL
D.	NULL
,	NULL
Dynan	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1984	NULL
)	NULL
Nature	NULL
812	NULL
,	NULL
409-413	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
Inuzuka	NULL
,	NULL
M.	NULL
,	NULL
Shigesada	NULL
,	NULL
K.	NULL
,	NULL
Oikawa	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Jpn	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

88	NULL
,	NULL
714-722	NULL
Kamachi	NULL
,	NULL
Y.	NULL
,	NULL
Ogawa	NULL
,	NULL
E.	NULL
,	NULL
Asano	NULL
,	NULL
M.	NULL
,	NULL
Ishida	NULL
,	NULL
S.	NULL
,	NULL
Murakami	NULL
,	NULL
Y.	NULL
,	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
Ito	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Shigesada	NULL
,	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

64	NULL
,	NULL
4808-4819	NULL
Liu	NULL
,	NULL
P.	NULL
,	NULL
Tarle	NULL
,	NULL
8	NULL
.	NULL

A.	NULL
,	NULL
Hajra	NULL
,	NULL
A.	NULL
,	NULL
Claxton	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
Marlton	NULL
,	NULL
P.	NULL
,	NULL
Freedman	NULL
,	NULL
M.	NULL
,	NULL
Siciliano	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
F.	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
261	NULL
,	NULL
1041-1044	NULL
Satake	NULL
,	NULL
M.	NULL
,	NULL
Nomura	NULL
,	NULL
S.	NULL
,	NULL
Yamaguchi-Iwai	NULL
,	NULL
Y.	NULL
,	NULL
Takahama	NULL
,	NULL
Y.	NULL
,	NULL
Hashimoto	NULL
,	NULL
Y.	NULL
,	NULL
Niki	NULL
,	NULL
M.	NULL
,	NULL
Kitamura	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Ito	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
1662-1670	NULL
Towler	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Bennett	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
Rodan	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

8	NULL
,	NULL
614-624	NULL
Towler	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Rutledge	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Rodan	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

8	NULL
,	NULL
1484-1493	NULL
Pavlin	NULL
,	NULL
D.	NULL
,	NULL
Lichtler	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Bedalov	NULL
,	NULL
A.	NULL
,	NULL
Kream	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Harrison	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Thomas	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
Gronowicz	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Clark	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Woody	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
Rowe	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

116	NULL
,	NULL
227-236	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
A	NULL
PEBP2/AML-1-related	NULL
Factor	NULL
Increases	NULL
Osteocalcin	NULL
Promoter	NULL
Activity	NULL
through	NULL
Its	NULL
Binding	NULL
to	NULL
an	NULL
Osteoblast-specific	NULL
cis-	NULL
Acting	NULL
Element	NULL
Valérie	NULL
Geoffroy	NULL
,	NULL
Patricia	NULL
Ducy	NULL
and	NULL
Gérard	NULL
Karsenty	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1995	NULL
,	NULL
270:30973-30979.	NULL
doi	NULL
:	NULL
10.1074/jb0.270.52.30973	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/270/52/30973	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
28	NULL
references	NULL
,	NULL
17	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

